(Reuters) – Teva Pharmaceutical Industries Ltd stated on Monday a U.S. court rejected 4 of the Israel-based drugmaker’s claims of patent infringement on its top-selling a number of sclerosis remedy.
The rejection comes 4 months after U.S. patent officers invalidated three patents on its drug Copaxone, in response to challenges by pharmaceutical firm Mylan NV, which has been making an attempt to market a generic model of the drug.
All asserted claims of Teva have been invalid, the U.S. District Court Of Delaware stated in a ruling on Monday.
The patents, which expire in 2030, cowl a 40-milligram injection of Copaxone that sufferers administer 3 times every week.
Generics might solely be bought after a drug’s patents expire or are invalidated by means of litigation.
However, Teva stated it deliberate to attraction the choice.
U.S.-listed shares of Teva have been down virtually 9 % in after-hours buying and selling, whereas Mylan’s shares edged up marginally.
(Reporting by Sruthi Shankar and Sangameswaran S in Bengaluru; Editing by Bill Rigby)